CORPORATE PRESENTATION MAY 2020

ABOUT US

2

Pharmadelic Labs is a biotech company focusing onimproving and patenting engineering processes for thebiosynthesis of compounds - primarily psilocybin, thepsychoactive component ofmagic mushrooms.

Changes to global attitude in the last decade has seenlegalization, followed by huge market growth, ofmedicines employing previously prohibited substances– cannabis being the leadingexample.

Now, leading scientists, academic institutions, andgovernment administrations are turning their attentionto the benefits of psilocybin as a potential treatment forthe global problems of mental health and end of life care.The ability to produce this molecule quickly,economically and cleanly, as Pharmadelic Labs is aimingto achieve, will be in high demand when psilocybingains widespread acceptance.

GOALPharmadelic Labs aims to develop a portfolio of intellectual property around biosynthesis pathways for creating compounds. This has great potential for application in the pharmaceuticals industry. The company's patent portfolio will developas follows:

1. File for provisional patent applications2. Continue to update patents as technology develops

3. Strengthen existing patents with further applications around biosynthesis pathways as results are known

Here’s how the biosynthesis of psilocybin works:

Step 1:Order synthetic DNA from hallucinogenic

mushrooms

Step 2:Install DNA into

genome of industrial brewing yeast

Step 3: Cultivate yeast on a largescale

Step 4:Extract psilocybin

Step 5:Create pharmaceutical

products

3

CLEANQUICK

THE OPTIMAL PROCESS

4

Pharmadelic Labs’ biosynthesis process is clean and economical, and much quicker than cultivating mushrooms by themselves– 3 days rather than 10 weeks. It also ensures consistent levels of psilocybin and is safe due to yeast’s status as Generally Recognized AsSafe (GRAS).

Pharmadelic Labs will also be providing an effective alternative to chemical synthesis. Chemical synthesis of psilocybin costs upwards of $7,000 per gram, which is far more expensive than our methods.1

SAFECHEAP

1 https://qz.com/1235963/scientists-who-want-to-study-psychedelic-mushrooms-have-to-pay-7000-per-gram/

PSILOCYBINPsilocybin is a psychoactive substance found in around200 species of mushroom. Much of the science remainssurrounding the molecule as-yet unexplored, but it has beentheorized that psilocybin works with the body’s serotoninsystem to heighten emotional responses, which helps toactively confront mental health issues such as depression.

More and more studies are examining the properties of thismolecule, and the seismic effects that it can have on the hugeglobal problem of treating mental health.

HISTORYPsilocybin was designated Schedule I in 1970 Criminal Substances Act, marking it a drug with“no currently accepted medical use and a high potential for abuse”. However, this was largely apolitically motivated decision made to oppose 1960s counterculture.

An article published by Johns Hopkins University in 2018 recommended that psilocybin bereclassified as Schedule IV – a drug with “low potential for abuse and low risk of dependence”.

5

THE MARKET - MENTAL HEALTHMental health problems are increasingly recognised as one of the biggest medical problems in the world. This costs countries both directly, through medication and hospitalization, and indirectly, through productivity losses.

10Suicide was the tenth-leading cause

of death in the US in 2017(Centers for DiseaseControl)

$200,000,000,000Mental health costs the US economy nearly $200 billion USD each year

(Forbes)

$13,500,000,000The global antidepressant drugsmarket was estimated to be over $13.5 billion USD in 2018, and is predicted to rise to

nearly $16 billion USD by 2025

(Brand Essence Research)

43,000,000In any given year, over 18% of US adults suffer from mental illness

(healthypeople.gov)

6

ADVANTAGES IN TREATMENTEarly studies indicate that psilocybin possesses huge advantages over existing treatments for mental health problems.

NOTPHYSICALLY ADDICTIVE

LOWRATES OF

ABUSE

FEW SIDE EFFECTS

Ongoing clinical trials are discovering the uses ofpsilocybin in the treatment of addiction and othermental health problems. Watch the recent 60Minutes documentary (broadcast 13th October2019) below that explores current efforts to treatharmful mental health issues.

https://www.cbsnews.com/news/psychedelic-drugs-lsd-active-agent-in-magic-mushrooms-to-treat-addiction-depression-anxiety-60-minutes-2019-10-13/

7

RESEARCHNumerous studies have already been published about the potential benefits of psychoactive substances (including psilocybin) for mental health. Examples of research can be found here.

Ross, Stephen, et al. “Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.” Journal of psychopharmacology 30.12 (2016): 1165-1180

Griffiths, Roland R., et al. “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.” Journal of psychopharmacology 30.12 (2016): 1181-1197

Carhart-Harris, Robin L., et al. “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.” The Lancet Psychiatry 3.7 (2016): 619-627

Carhart-Harris, R. L., et al. “Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.” Psychopharmacology 235.2 (2018):399-408

Belouin, Sean J., and Jack E. Henningfield. “Psychedelics: Where we are now, why we got here, what we must do.” Neuropharmacology 142 (2018): 7-19

Johnson, Matthew W., et al. “The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.” Neuropharmacology 142(2018): 143-166

8

COMPETITIONOwing to tight regulations on prohibited substances such as psilocybin, there are very few competitors in this area.

Founded in 2018, the company specializes in researchingpreviously stigmatized compounds for treating mental health.The company currently focuses on arketamine therapies fordepression.

ATAI closed a $43 million USD Series B funding round in March2019.

9

In 2018, Compass Pathways was granted “breakthrough therapy”designation by the FDA – this allowed it to research the potentialof psilocybin in treating depression.

The company has been invested in by established characters suchas Peter Thiel.

CaaMTech is one of the few companies to have intellectualproperty in the psychedelic space.

The company focuses on the properties of DMT, but alsoresearches the different psychedelic effects of mushroomvarieties.

This company was founded by the world-renowned mycologistPaul Stamets, a leading authority on hallucinogenic mushroomsand their properties. His 1996 book, Psilocybin Mushrooms ofthe World, is still considered one of the best on the topic.

Stamets has several patents relating to the use of psilocybinmushrooms as a pharmaceutical, which he hopes to commercializeafter further legalization.

PATENTINGThe general prohibition of psilocybin does not limit opportunities to develop an intellectual property portfolio. Companies can get ahead of the game with early research, and patent their ideas now.

Patents for methods for the biosynthesis of psilocybin,in addition to uses of psilocybin in health treatment,are availablefor companiesto applyfornow.

Very few companies are active in this area - a recentexample was published by a renowned mycologist inJanuary2018.

Pharmadelic Labs will surge ahead of competition bygathering intellectual property in the psilocybin space.The secondary aim of the company will be to gathercomposition of matter patents for derivatives ofpsilocybin.

10

THE NEXT PHASE

1 Month Order laboratory equipment, draft patent applications

3 MonthsComplete laboratory

setup, make first patent applications

12 Months Optimize biosynthesis of psilocybin, make additional

patent applications

Pharmadelic Labs has the next steps planned out

11

TEAM

GEORGE ANSTEY CEO

For the past decade, George’s entrepreneurial mind has beenfocused on the booming cannabis industry: contracting withcommercial license holders like Broken Coast Cannabis, a medicalcannabis company bought by Aphria for $230 million CAD in2018. George now consults on compliance matters for early-stagecannabis companies, helping those organizations to navigatethe license application requirements set by Health Canada.This experience in guiding new industries will be invaluable inpromoting psilocybin.

George is from Victoria BC, on the West Coast of Canada and waseducated at the UniversityofVictoria’s School of Business. Outsideof work, George can be found hiking, fishing and mushroom-hunting in the coastal rainforests of the Pacific Northwest.

12

BRENT STAPLES CSO

Brent has been heavily involved in metabolic engineering ofindustrial brewing yeasts for the development of novelfermented products. In addition to this, he focuses on theanalysis of metabolites corresponding to genomic changes. Heis now working on engineering synthetic metabolic pathwaysfor the biosynthesis high-value molecules in microorganisms tomeet the growing demand for cleaner, renewable chemistries.It is Brent’s enviable knowledge in this area that has allowedPharmadelic Labs to develop its innovative method ofbiosynthesising psilocybin.

Brent is from Victoria, Canada, where he studied biochemistry atthe University of Victoria, with a focus on synthetic biology andmedicinal chemistry.

TEAM

G. SCOTT WALKER MEMBER OF THE BOARD

Scott is a senior management consultant with over 30 years’experience in start-ups, corporate management, governmentrelations, and business development. He has diverse experiencein the Government, Defence, Information Technology, Finance,and Services sectors. Scott spent over 25 years in Ottawa as alobbyist, contractor, advisor and consultant to the CanadianFederal Government, international governments and Fortune1000 Corporations. He has worked on many major governmentcrown projects, and for a select group of Defence clients.

Since2012, Scotthasbeen Senior Partnerof MidpointVentures. Heworks as a management consultant, primarily within the cannabisindustry. He has helped over a dozen medical and recreationalcannabis businesses secure capital, licensing and strategicpartnerships in North America, South America and Europe. Scottco-founded the Canadian Medical Cannabis Industry Association(now Cannabis Canada association) and was a Board Member for3 years.

13

J. H. LIPTON CFO

J.H. Lipton is an expert in his field, having practiced corporatetax and securities law for over three decades. He was called tothe Bar in both the UK and Canada as senior counsel and holdsfurther business qualifications in the form of an MBA and CFA.

Previously, Lipton has held posts as a regulator, manager,investment banker and senior executive across a wide anddiversified group of companies and industries. With extensiveexperience in capital markets and technology he lends managerialcapacity and credibility to Pharmadelic Labs’ corporate endeavors.Leaning on several decades of legal and corporate experience hewill act as Chief Financial Officer and as general counsel.

TEAM

MATT HOLYOAKVICE PRESIDENT OF BUSINESS DEVELOPMENT

Matt graduated with a degree in History from the University ofOxford, the oldest university in the English-speaking world andranked by Times Higher Education as the top institution ofhigher education in the world for 2019. The intense workloadof his degree has prepared Matt with an excellent work ethicand a deeper understanding of the historical trends underlyingthe world of business.

With an incisive mind and attention to detail, Matt has helped takemany companies from their earliest stages to late-stage financingand public filing. Much of his work in the past year has beenfocused on the burgeoning cannabis industry, which will translatewell to guiding companies through the nascent psychedelicsmarket.

LAWRENCE PEMBLEDIRECTOR

Lawrence Pemble has comprehensive experience in successfullycreating, financing and developing biotechnology businesses. Hehas led companies and individual projects from the developmentand discovery phases through to financing and further clinicaldevelopment.

Lawrence is the principal of a Life Science private equity firm,Theseus Capital Ltd, and also acts as COO of publicly traded andprivate biotechnology and medical technology companies. He iscurrently COO of 180 Life Sciences Corp, a biotech company thatis due to list on NASDAQ at a pre-money valuation ofapproximately USD $220M by summer 2020.

Lawrence served for over six years in the Royal MarineCommandos, leading front-line operations in Sierra Leone,Somalia, Iraq and Afghanistan. Lawrence completed his Master ofBusiness Administration degree at the University of Oxford’sprestigious Saïd Business School with distinction.

14

USE OF PROCEEDS - YEAR 1Pharmadelic Labs is looking to raise $1,000,000 CAD. This raise will be used for:

$25,000Upgrading

laboratory for R&D space

$90,000Buying inputs

$265,000Lease and equipment

$370,000Salaries

$160,000Legal fees

$90,000Insurance and travel

15

USE OF PROCEEDS - YEAR 2Pharmadelic Labs will look to raise $2,000,000 CAD in its second year. This raise will be used for:

$50,000Expanding

research to other tryptamines

$500,000Creating a

production space

$100,000Buying inputs

$100,000Purchasing

consumables

$750,000Salaries

$500,000Legal fees

16

CORPORATE STRUCTURE

Top Co.Pharmadelic Labs Corp.

(Nevada)Intellectual Property

Operating Co.Pharmadelic Labs

(British Columbia)Academic ResearchPartnership

100%

100%

17

Pharmadelic Labs Corp.3773 Howard Hughes Pkwy Ste 500

Las Vegas, NV89169-6014